VBI Vaccines (formerly SciVac Therapeutics)
Cambridge
About VBI Vaccines (formerly SciVac Therapeutics)
SciVac Therapeutics changes its name to VBI Vaccines Sci-B-Vac is a commercial stage hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus and is free of any next-generation adjuvant. Sci-B-Vac offers rapid onset of protection, high levels of anti-HBV antibodies, and can be administered at lower doses than competing HBV vaccines. Sci-B-Vac is approved in Israel and in 14 other countries and has demonstrated a favorable safety and efficacy profile in over 300,000 patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $468.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: cve:VBV
- Website: vbivaccines.com
- Phone: +1 617-830-3031
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vbi-vaccines-formerly-scivac-therapeutics-2229638 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.